.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Choosing the right antipsychotic choice for females experiencing their first episode of psychosis (FEP) is vital for long-term health. Traditional guidelines often lack sex-specific details. However, women face higher risks of hyperprolactinemia and metabolic issues. These side effects cause significant distress and impact medication adherence. Therefore, a multidisciplinary panel developed new recommendations to address these unique needs. Specifically, the panel prioritized safety profiles over traditional prescribing habits.
Many common medications, such as olanzapine and risperidone, pose significant risks for female patients. Instead, the guideline recommends aripiprazole as the primary first-line treatment. This medication effectively manages symptoms without causing severe hormonal or metabolic shifts. Notably, shared decision-making ensures that patients and doctors select the most appropriate therapy together. Moreover, clinicians must consider the long-term physical risks associated with weight gain and endocrine disruption. Adopting a sex-sensitive approach improves treatment equity and long-term recovery outcomes.
Clinicians should avoid using medicines with high prolactin-elevation risks as first-line options for females. This list includes amisulpride, paliperidone, and most first-generation antipsychotics. Additionally, doctors should utilize shared decision-making tools for both adults and adolescents. These tools help balance therapeutic efficacy with individual safety concerns. Furthermore, regular monitoring of cardiometabolic markers and prolactin levels remains essential. Consequently, following these guidelines will lead to safer prescribing and better patient satisfaction.
Aripiprazole is preferred because it has a consistently favorable profile regarding prolactin levels and cardiometabolic health compared to other second-generation antipsychotics.
These medications are associated with higher risks of significant weight gain, metabolic syndrome, and hyperprolactinemia, which can lead to menstrual irregularities and long-term health issues.
By minimizing distressing side effects, sex-sensitive prescribing improves treatment acceptability and adherence, which are critical for preventing relapse in first-episode psychosis.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. It is not a substitute for professional clinical judgment. Refer to the latest local and national guidelines for clinical practice.
References
Hynes-Ryan C et al. Clinical Practice Guideline on the Choice of First Antipsychotic Medicine for Females Experiencing a First-Episode of Psychosis. Schizophr Bull. 2026 Mar 07. doi: undefined. PMID: 41793755.
Seeman MV. Antipsychotic treatment for women with schizophrenia. Expert Rev Neurother. 2021;21(7):791-807.
Cooper D et al. Antipsychotic-induced hyperprolactinaemia: synthesis of world-wide guidelines. Lancet Psychiatry. 2017;4(2):153-163.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
International guidelines now recommend aripiprazole as the preferred first-line antipsychotic for females to avoid metabolic and hormonal side effects....
6 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
